Pharmaceutical / Pharmaceuticals / Rare Diseases / Pharma / Boston blog main / National blog main / Raleigh-Durham / Raleigh-Durham blog main / Raleigh-Durham top stories / BioCryst Pharmaceuticals / Biotech / cancer / clinical trials / deals / Hereditary Angiodema / Idera Pharmaceuticals / Life Sciences / M&A / Melanoma / RA Capital / rare disease drugs

BioCryst Drops Idera Pharma Merger After Shareholders Veto Deal

Posted on: Jul 11, 2018   |   Posted by: Biotech Mag Top

BioCryst Drops Idera Pharma Merger After Shareholders Veto Deal

BioCryst Pharmaceuticals is ending a plan to merge with Idera Pharmaceuticals and form a single company focused on rare diseases. Durham, NC-based BioCryst terminated the...

Continue reading ...